Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
Shooting injures 2 at Missouri high school graduation ceremony
CAPE GIRARDEAU, Mo. (AP) — Two people were injured when gunfire broke out during a high school gradu2024-05-21China Improves Legislation to Protect Children in Cyberspace
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21People Pay Tribute to Deceased on Tomb
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Sitting Tai Chi Exercises Help Improve Stroke Recovery: Study
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21What's next for Iran after death of its president in crash?
JERUSALEM (AP) — The death of Iran’s president is unlikely to lead to any immediate changes in Iran’2024-05-21Art Class Enables Children with Autism to Socialize
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment